Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Pfizer

Status and phase: Completed; Phase 2

Conditions: Pancreatic Neuroendocrine Tumors

Treatments: Drug: Sunitinib

Study type: Interventional

Funder types: Industry

Identifiers

NCT01121562

A6181193

Details and patient eligibility

About

The purpose of the study is to evaluate the effect of Sunitinib on the clinical benefit response rate.

Enrollment: 12 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients must have advanced (unresectable or metastatic) biopsy-proven pancreatic NET (Neuroendocrine Tumor)

Exclusion criteria

• Patients with poorly differentiated neuroendocrine cancer are not eligible

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

12 participants in 1 patient group

Sunitinib arm

Experimental group

Treatment:

Drug: Sunitinib